SCHEMBL4871137

SCHEMBL4871137

COC(=O)c1cc(/C=C/C(=O)N(C)C)cc2c1OC(c1ccccc1)(c1ccccc1)O2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IP6K1 Q92551 1/20 0.41
IP6K2 Q9UHH9 1/20 0.41
APP P05067 1/20 0.39
KDM4E B2RXH2 3/20 0.37
OPRM1 P35372 1/20 0.36
OPRL1 P41146 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
NR4A2 P43354 1/20 0.35
TRPM8 Q7Z2W7 3/20 0.35
LMNA P02545 2/20 0.35
ALDH1A1 P00352 2/20 0.35
GAA P10253 1/20 0.35
HPGD P15428 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
CYP1A2 P05177 1/20 0.34
CYP2C19 P33261 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4871141 1.00 IP6K1 (0.41) IP6K1IP6K2APPKDM4EOPRM1
SCHEMBL4865191 0.89 IP6K1 (0.43) IP6K1IP6K2APPKDM4EOPRM1
SCHEMBL4865182 0.89 IP6K1 (0.43) IP6K1IP6K2APPKDM4EOPRM1
SCHEMBL4868406 0.76 KDM4E (0.42) KDM4ESMN1; SMN2MEN1KMT2ANR4A2
SCHEMBL4868416 0.76 ALDH1A1 (0.41) KDM4EMEN1KMT2ANR4A2LMNA
SCHEMBL7834819 0.74 KDM4E (0.57) KDM4ESMN1; SMN2LMNAALDH1A1GAA
SCHEMBL4863014 0.74 KDM4E (0.37) KDM4ENR4A2LMNAALDH1A1HPGD
SCHEMBL4867441 0.73 CNR1 (0.41) KDM4ESMN1; SMN2MEN1KMT2ALMNA
SCHEMBL8285503 0.73 TRPA1 (0.47) KDM4ESMN1; SMN2NPC1KMT2ALMNA
SCHEMBL4867176 0.73 NR4A2 (0.41) KDM4ESMN1; SMN2MEN1KMT2ANR4A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7319101-B2 COMT inhibitors for the treatment of depression and impaired cognition HOFFMANN-LA ROCHE INC. (US) 2008-01-15 US disclosed
US-7319101-B2 COMT inhibitors for the treatment of depression and impaired cognition HOFFMANN-LA ROCHE INC. (US) 2008-01-15 US disclosed
US-7319101-B2 COMT inhibitors for the treatment of depression and impaired cognition HOFFMANN-LA ROCHE INC. (US) 2008-01-15 US disclosed
EP-1697394-B1 COMT INHIBITORS HOFFMANN LA ROCHE (CH) 2007-03-21 EP disclosed
EP-1697394-B1 COMT INHIBITORS HOFFMANN LA ROCHE (CH) 2007-03-21 EP disclosed
EP-1697394-A2 COMT INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2006-09-06 EP disclosed
WO-2005058228-A2 COMT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 WO disclosed
WO-2005058228-A2 COMT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 WO disclosed
US-20050137162-A1 New COMT inhibitors for the treatment of depression and impaired cognition F. HOFFMANN-LA ROCHE AG (CH) 2005-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137162-A1 New COMT inhibitors for the treatment of depression and impaired cognition COMT, MAOB, TPH1 IP6K1 4234/4885IP6K2 4479/4885APP 777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.